Medpace Holdings, Inc. President and CEO August J. Troendle filed a Form 4 on September 23, 2026, disclosing the sale of 70,901 shares of common stock across two trading days.

Key Highlights

  • First sale: 21,883 shares sold on September 21, 2026, at a weighted average price of $623.29, with individual transactions ranging from $620.00 to $625.91.
  • Second sale: 49,018 shares sold on September 22, 2026, at a weighted average price of $628.11, with individual transactions ranging from $620.00 to $632.815.
  • Direct ownership after sales: Troendle directly holds 433,372 shares of common stock following the reported transactions.
  • Indirect ownership: An additional 4,733,019 shares are held indirectly through Medpace Investors, LLC, of which Troendle is the sole manager and controlling unit holder.
  • Transaction basis: Both sales were effected pursuant to a limit order placed during an open window period, according to the filing.

Troendle's Share Sales and Remaining Ownership in Medpace Holdings

According to the Form 4 filed with the SEC, August J. Troendle, President and CEO of Medpace Holdings, Inc. (NASDAQ:MEDP), disposed of a combined 70,901 shares of common stock over two consecutive trading days. The transactions were coded "S" (sale) in Table I of the filing. The first sale on September 21, 2026, involved 21,883 shares at a weighted average price of $623.29 per share, with individual transaction prices ranging from $620.00 to $625.91. Following that sale, Troendle's direct holdings stood at 482,390 shares.

The second sale on September 22, 2026, involved 49,018 shares at a weighted average price of $628.11 per share, with prices ranging from $620.00 to $632.815 across multiple transactions. After this second sale, his direct beneficial ownership was reduced to 433,372 shares. The filing notes that both sets of transactions were carried out via a limit order placed during an open window period. Troendle has undertaken to provide full pricing details for each transaction to the issuer, any security holder, or SEC staff upon request.

Separately, the filing reports that 4,733,019 shares of common stock are held indirectly through Medpace Investors, LLC. According to the filing, Troendle "is the sole manager and controlling unit holder of Medpace Investors, LLC" and holds "sole voting and investment control with respect to the securities held by MPI." The filing states he "disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein." The Form 4 was signed by Stephen P. Ewald as attorney-in-fact for Troendle on September 23, 2026.

What Was Disclosed

The filing disclosed two open-market sales of Medpace Holdings common stock by President and CEO August J. Troendle totaling 70,901 shares at weighted average prices of $623.29 and $628.11, with direct holdings of 433,372 shares remaining after both transactions.